Tratamiento antiinflamatorio en la depresión: una revisión sistemática

Autores/as

DOI:

https://doi.org/10.25118/2763-9037.2024.v14.1156

Palabras clave:

terapéutica, depresión, inflamación, tratamiento, antiinflamatorio, inmunidad, psiquiatría

Resumen

Introducción: La alta prevalencia de depresión en la población mundial, asociada a la alta morbilidad del trastorno, hace necesario el desarrollo de tratamientos efectivos. Estudios recientes han demostrado la correlación entre la inflamación y el desarrollo de estados depresivos. Objetivos: Evaluar el uso de sustancias antiinflamatorias en el manejo de pacientes con depresión uni y bipolar. Metodología: Este es una revisión sistemática con análisis cualitativo basado en el protocolo Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). La búsqueda se realizó en Biblioteca Virtual em Saúde y PubMed. Se seleccionaron siete estudios. Resultados: El número de estudios que mostraron eficacia de celecoxib e infliximab fue cercano al de los que no lo fueron, los biomarcadores séricos se relacionaron con la disminución en las escalas de depresión con ambos. Conclusiones: Los resultados sobre la efectividad del tratamiento antiinflamatorio en la depresión aún no son concluyentes debido a la heterogeneidad de las investigaciones y al bajo número de estudios disponibles.

 

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Biografía del autor/a

Bárbara Dicarlo Costa Braga, Graduanda, Medicina, Universidade Federal da Bahia, UFBA, Bahia, BA, Brasil

Bruna Teixeira da Costa, Graduanda, Medicina, Universidade Federal da Bahia, UFBA, Bahia, BA, Brasil

Graduado em Medicina

Katiene Rodrigues Menezes de Azevedo, Médica Psiquiatra, Mestre em Psicologia da Saúde, Universidade Federal da Bahia, UFBA, Bahia, BA, Brasil

Psiquiatra, Máster en Psicología de la Salud

Citas

World Health Organization. World mental health report: transforming mental health for all. Geneva: World Health Organization; 2022. https://www.who.int/publications/i/item/9789240049338

Zachariae R. Psychoneuroimmunology: a bio-psycho-social approach to health and disease. Scand J Psychol. 2009;50(6):645-51. https://doi.org/10.1111/j.1467-9450.2009.00779.x PMID:19930265 DOI: https://doi.org/10.1111/j.1467-9450.2009.00779.x

Patel A. Review: the role of inflammation in depression. Psychiatr Danub. 2013;25 Suppl 2:S216-23. PMID:23995180

Lynall ME, Turner L, Bhatti J, Cavanagh J, de Boer P, Mondelli V, Jones D, Drevets WC, Cowen P, Harrison NA, Pariante CM, Pointon L, Clatworthy MR, Bullmore E; Neuroimmunology of Mood Disorders and Alzheimer’s Disease (NIMA) Consortium. Peripheral blood cell-stratified subgroups of inflamed depression. Biol Psychiatry. 2020;88(2):185-96. https://doi.org/10.1016/j.biopsych.2019.11.017 - PMID:32000983 DOI: https://doi.org/10.1016/j.biopsych.2019.11.017

Jeon SW, Kim YK. Inflammation-induced depression: its pathophysiology and therapeutic implications. J Neuroimmunol. 2017;313:92-8. https://doi.org/10.1016/j.jneuroim.2017.10.016 PMID:29153615 DOI: https://doi.org/10.1016/j.jneuroim.2017.10.016

Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381-91. https://doi.org/10.1001/jamapsychiatry.2014.1611 - PMID:25322082 DOI: https://doi.org/10.1001/jamapsychiatry.2014.1611

Husain MI, Strawbridge R, Stokes PR, Young AH. Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis. J Psychopharmacol. 2017;31(9):1137-48. https://doi.org/10.1177/0269881117725711 - PMID:28858537 DOI: https://doi.org/10.1177/0269881117725711

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160 PMID:33781993 - PMCID:PMC8005925 DOI: https://doi.org/10.1136/bmj.n160

Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. https://doi.org/10.1001/2013.jamapsychiatry.4 - PMID:22945416 PMCID:PMC4015348 DOI: https://doi.org/10.1001/2013.jamapsychiatry.4

McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, Rosenblat JD, Brietzke E, Soczynska JK, Cosgrove VE, Miller S, Fischer EG, Kramer NE, Dunlap K, Suppes T, Mansur RB. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(8):783-90. https://doi.org/10.1001/jamapsychiatry.2019.0779 PMID:31066887 - PMCID:PMC6506894 DOI: https://doi.org/10.1001/jamapsychiatry.2019.0779

Baune BT, Sampson E, Louise J, Hori H, Schubert KO, Clark SR, Mills NT, Fourrier C. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: a 6-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol. 2021;53:34-46. https://doi.org/10.1016/j.euroneuro.2021.07.092 PMID:34375789 DOI: https://doi.org/10.1016/j.euroneuro.2021.07.092

Halaris A, Cantos A, Johnson K, Hakimi M, Sinacore J. Modulation of the inflammatory response benefits treatment-resistant bipolar depression: a randomized clinical trial. J Affect Disord. 2020;261:145-52. https://doi.org/10.1016/j.jad.2019.10.021 PMID:31630035 DOI: https://doi.org/10.1016/j.jad.2019.10.021

Edberg D, Hoppensteadt D, Walborn A, Fareed J, Sinacore J, Halaris A. Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. J Psychiatr Res. 2018;102:1-7. https://doi.org/10.1016/j.jpsychires.2018.02.004 PMID:29554535 DOI: https://doi.org/10.1016/j.jpsychires.2018.02.004

Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141(2-3):308-14. https://doi.org/10.1016/j.jad.2012.03.033 PMID:22516310 DOI: https://doi.org/10.1016/j.jad.2012.03.033

Mansur RB, Delgado-Peraza F, Subramaniapillai M, Lee Y, Iacobucci M, Rodrigues N, Rosenblat JD, Brietzke E, Cosgrove VE, Kramer NE, Suppes T, Raison CL, Chawla S, Nogueras-Ortiz C, McIntyre RS, Kapogiannis D. Extracellular vesicle biomarkers reveal inhibition of neuroinflammation by infliximab in association with antidepressant response in adults with bipolar depression. Cells. 2020;9(4):895. https://doi.org/10.3390/cells9040895 PMID:32268604 - PMCID:PMC7226726 DOI: https://doi.org/10.3390/cells9040895

Golan DE, Tashjian AH Jr, Armstrong EJ, Armstrong AW. Principles of pharmacology: the pathophysiologic basis of drug therapy. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2012.

Wang Z, Wu Q, Wang Q. Effect of celecoxib on improving depression: a systematic review and meta-analysis. World J Clin Cases. 2022;10(22):7872-82. https://doi.org/10.12998/wjcc.v10.i22.7872 PMID:36158469 - PMCID:PMC9372844 DOI: https://doi.org/10.12998/wjcc.v10.i22.7872

Halaris A, Hain D, Law R, Brown L, Lewis D, Filip M. Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression. Brain Behav Immun Health. 2023;30:100625. https://doi.org/10.1016/j.bbih.2023.100625 PMID:37181328 - PMCID:PMC10172701 DOI: https://doi.org/10.1016/j.bbih.2023.100625

Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171-86. https://doi.org/10.1097/psy.0b013e3181907c1b PMID:19188531 DOI: https://doi.org/10.1097/PSY.0b013e3181907c1b

Bavaresco DV, Uggioni MLR, Ferraz SD, Marques RMM, Simon CS, Dagostin VS, Grande AJ, da Rosa MI. Efficacy of infliximab in treatment-resistant depression: a systematic review and meta-analysis. Pharmacol Biochem Behav. 2020;188:172838. https://doi.org/10.1016/j.pbb.2019.172838 PMID:31837338 DOI: https://doi.org/10.1016/j.pbb.2019.172838

Rizzo FR, Musella A, De Vito F, Fresegna D, Bullitta S, Vanni V, Guadalupi L, Stampanoni Bassi M, Buttari F, Mandolesi G, Centonze D, Gentile A. Tumor necrosis factor and interleukin-1β modulate synaptic plasticity during neuroinflammation. Neural Plast. 2018;2018:8430123. https://doi.org/10.1155/2018/8430123 PMID:29861718 - PMCID:PMC5976900 DOI: https://doi.org/10.1155/2018/8430123

Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1355-61. https://doi.org/10.1016/j.pnpbp.2008.01.006 PMID:18316149 DOI: https://doi.org/10.1016/j.pnpbp.2008.01.006

Liguz-Lecznar M, Zakrzewska R, Kossut M. Inhibition of Tnf-α R1 signaling can rescue functional cortical plasticity impaired in early post-stroke period. Neurobiol Aging. 2015;36(10):2877-84. https://doi.org/10.1016/j.neurobiolaging.2015.06.015 PMID:26189092 DOI: https://doi.org/10.1016/j.neurobiolaging.2015.06.015

Yao R, Man Y, Lu Y, Su Y, Zhou M, Wang S, Gu X, Wang R, Wu Y, Wang L. Infliximab alleviates memory impairment in rats with chronic pain by suppressing neuroinflammation and restoring hippocampal neurogenesis. Neuropharmacology. 2024;245:109813. https://doi.org/10.1016/j.neuropharm.2023.109813 PMID:38110173 DOI: https://doi.org/10.1016/j.neuropharm.2023.109813

Zovetti N, Rossetti MG, Perlini C, Brambilla P, Bellani M. Brain ageing and neurodegeneration in bipolar disorder. J Affect Disord. 2023;323:171-5. https://doi.org/10.1016/j.jad.2022.11.066 PMID:36435402 DOI: https://doi.org/10.1016/j.jad.2022.11.066

Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry. 2009;22(1):32-6. https://doi.org/10.1097/yco.0b013e328315a561 - PMID:19122532 DOI: https://doi.org/10.1097/YCO.0b013e328315a561

Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206-15. https://doi.org/10.1016/j.bbi.2015.06.001 - PMID:26065825 - PMCID:PMC4566946 DOI: https://doi.org/10.1016/j.bbi.2015.06.001

Publicado

2024-08-09

Cómo citar

1.
Costa Braga BD, Costa BT da, Azevedo KRM de. Tratamiento antiinflamatorio en la depresión: una revisión sistemática. Debates em Psiquiatria [Internet]. 9 de agosto de 2024 [citado 2 de abril de 2025];14:1-19. Disponible en: https://revistardp.org.br/revista/article/view/1156

Número

Sección

Artículo de revisión

Plaudit